Newland says this is a tremendous opportunity for ANGLE, as he says ANGLE is the first company to potentially get FDA clearance for its platform that harvests live circulating tumor cells (CTCs) from a patient's blood.
ANGLE PLC submits its flagship Parsortix liquid biopsy diagnostic to the FDA
Quick facts: ANGLE PLC
Price: 53.1 GBX
Market Cap: £91.75 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE